Skip Navigation


European Heart Journal Advance Access originally published online on February 3, 2006
European Heart Journal 2006 27(5):510-511; doi:10.1093/eurheartj/ehi703
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/5/510    most recent
ehi703v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McLaughlin, V. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLaughlin, V. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

‘Raising the bar’ for the treatment of pulmonary arterial hypertension

Vallerie V. McLaughlin*

Pulmonary Hypertension Program, University of Michigan, 1500 E. Medical Center Drive, Women's Hospital, Room L3119, Ann Arbor, MI 48109-0273, USA

* Corresponding author. Tel: +1 734 936 5383; fax: +1 734 763 7390. E-mail address: vmclaugh@umich.edu

This editorial refers to ‘Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension’{dagger} by S. Provencher et al., on page 589

The first 10% of the full text of this article appears below.

Historically, idiopathic pulmonary arterial hypertension (IPAH, formerly referred to as primary pulmonary hypertension) has been considered a fatal disease. The natural history of IPAH was well described by the American National Institutes of Health (NIH) Registry of the 1980s. A median survival of 2.8 years with estimated single-year survival rates at 1, 3, and 5 years of 68, 48, and 35%, respectively were documented.1 Predictors of a poor prognosis included advanced functional class and haemodynamics (right atrial pressure, cardiac index, and pulmonary artery pressure). Fortunately, much has changed since the 1980s. We now several novel therapeutic options including prostacyclins, endothelin receptor antagonists, and phosphodiesterase type-5 inhibitors, all of which have improved exercise endurance in clinical trials. Surely, we have improved survival in IPAH, haven't we?

Classically, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
Steeve Provencher, Olivier Sitbon, Marc Humbert, Ségolène Cabrol, Xavier Jaïs, and Gérald Simonneau
EHJ 2006 27: 589-595. [Abstract] [FREE Full Text]